Sagimet Biosciences Inc. (NASDAQ: SGMT)
$3.66
+0.2600 ( +7.65% ) 425.5K
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Market Data
Open
$3.66
Previous close
$3.40
Volume
425.5K
Market cap
$116.49M
Day range
$3.35 - $3.67
52 week range
$2.13 - $20.71
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Nov 20, 2023 |
10-q | Quarterly Reports | 67 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 43 | Oct 23, 2023 |
8-k | 8K-related | 45 | Sep 27, 2023 |
4 | Insider transactions | 1 | Sep 08, 2023 |
8-k | 8K-related | 45 | Aug 21, 2023 |
10-q | Quarterly Reports | 72 | Aug 21, 2023 |
8-k | 8K-related | 32 | Aug 10, 2023 |
8-k | 8K-related | 1 | Jul 27, 2023 |